MetaCap

MBX Biosciences (MBX) vs Arcus Biosciences (RCUS)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

MBX Biosciences (MBX) has outperformed Arcus Biosciences (RCUS) over the past year, gaining 83.0% versus a loss of 29.2%. MBX Biosciences is the larger company by market cap ($2.46 billion vs $2.25 billion), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

MBX+82.98%RCUS-29.16%
+171%+66%-39%
Nov 21, 20251 yearNov 20, 2026
MBX+109.51%RCUS-12.98%
+203%+58%-88%
Sep 9, 20245 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

MBX versus RCUS key metrics
MetricMBXRCUS
Share price$49.55$15.62
Market cap$2.46B$2.25B
1-day change-7.23%-1.01%
YTD return+57.10%-34.45%
1-year return+82.98%-29.16%
5-year return—-66.31%
EPS (TTM)$-3.03$-3.64
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$247.00M
Revenue growth (YoY)—-4.26%
Net income (latest FY)$-87.00M$-353.00M
Operating margin—-156.28%
Net margin—-142.91%
52-week high$72.64$31.74
52-week low$26.14$15.56
Distance from 52-week high-31.79%-50.78%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+91.91%+162.48%
Average volume532.80K1.85M
Shares outstanding49.66M143.99M
Employees63601
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • MBX has outperformed RCUS by 112.1 percentage points over the past year.

About MBX Biosciences

MBX stock →

MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is Canvuparatide (MBX 2109), a parathyroid hormone peptide prodrug, which is in Phase 3 clinical trial for the treatment of chronic hypoparathyroidism.

Health Care · Biotechnology: Pharmaceutical Preparations · 63 employees

About Arcus Biosciences

RCUS stock →

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's development product portfolio includes Casdatifan, a HIF-2a inhibitor for the treatment of kidney cancer; Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial for lung and gastrointestinal cancers; and Zimberelimab, an anti-PD-1 antibody.

Health Care · Biotechnology: Pharmaceutical Preparations · 601 employees

MBX vs RCUS FAQ

Which is bigger, MBX Biosciences or Arcus Biosciences?

MBX Biosciences (MBX) is larger, with a market capitalization of $2.46B compared with $2.25B for Arcus Biosciences (RCUS).

Which stock has performed better over the past year, MBX or RCUS?

MBX returned +82.98% over the past 12 months, compared with -29.16% for RCUS (price return, excluding dividends). Past performance does not predict future results.

Are MBX Biosciences and Arcus Biosciences in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons